Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation
NCT04589286 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2023-07-20
Summary
Autologous stem cell transplantation (SCT) is the standard of care for fit multiple myeloma (MM) patients; however, the first 100 days after SCT are marked by extensive life disruptions. We have found a 56% relative increase in the use of high-risk benzodiazepine and Z-class (B/Z) drugs for anxiety and insomnia among MM patients during this period. Digital life coaching (DLC), whereby trained coaches work longitudinally with patients through phone calls and text messages to accomplish personal goals, may be able to target anxiety and insomnia in a more integrative manner. This study will investigate whether peri-SCT DLC can lower B/Z usage and improve patient-reported well-being.
Conditions
- Multiple Myeloma
- Stem Cell Transplant
Interventions
- BEHAVIORAL
-
Pack Health's Digital Life Coaching (DLC)
Pack Health smartphone-based DLC platform
- OTHER
-
Electronic Handouts
Generic wellness-related electronic handouts
Sponsors & Collaborators
-
American Society of Clinical Oncology
collaborator OTHER -
University of California, San Francisco
lead OTHER
Principal Investigators
-
Rahul Banerjee, MD · University of California, San Francisco
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-12-29
- Primary Completion
- 2023-06-30
- Completion
- 2023-06-30
Countries
- United States
Study Locations
More Related Trials
-
A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders
NCT06126341 ·Status: ACTIVE_NOT_RECRUITING
-
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
NCT03352765 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
NCT05956457 ·Status: RECRUITING ·Phase: NA
-
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
NCT01142232 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Dietary Study for People With Multiple Myeloma
NCT07226609 ·Status: RECRUITING ·Phase: NA
-
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761 ·Status: RECRUITING
-
Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)
NCT05276622 ·Status: TERMINATED
-
Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)
NCT03795597 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
NCT00112827 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
NCT02506959 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
NCT01208662 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01731886 ·Status: COMPLETED ·Phase: PHASE4
-
ASCT With Nivolumab in Patients With Multiple Myeloma
NCT03292263 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT01936090 ·Status: COMPLETED ·Phase: PHASE1
-
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
NCT03315026 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy
NCT02288741 ·Status: COMPLETED ·Phase: PHASE3
-
Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years
NCT01671826 ·Status: UNKNOWN
-
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L
NCT00807599 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
NCT03328936 ·Status: WITHDRAWN ·Phase: PHASE2
-
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT01605032 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
NCT02331368 ·Status: COMPLETED ·Phase: PHASE2
-
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
NCT01241708 ·Status: COMPLETED ·Phase: PHASE3
-
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
NCT00114101 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
NCT04822337 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
NCT04999085 ·Status: COMPLETED ·Phase: NA